Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken.
Watch this short video to learn why!

FDA Nonclinical Testing Terminology Rule: Key Regulatory Updates for Drug and Biologic Submissions

$49.99

This course delivers a focused breakdown of the FDA’s direct final rule that replaces outdated terminology in human drug and biological product regulations. Learn exactly how to update your regulatory submissions and internal documentation by adopting ‘nonclinical’ instead of ‘animal’, ‘preclinical’, or ‘in vitro’ in all relevant contexts. Master the new definitions as they apply to IND, NDA, BLA, and postmarketing materials. Ensure your organization is prepared for the compliance deadline and avoids costly regulatory delays.

In this course you will learn the following:
* Identify the key terminology changes and their regulatory context.
* Understand the expanded definition of “nonclinical test” and “nonclinical study.”
* Apply the new terminology in regulatory submissions and communications.
* Recognize the impact of these changes on compliance and reporting.
* Understand the consequences of non-compliance with the updated regulations.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.

Why This Course is Important
Without this course, you risk non-compliance with the FDA’s updated terminology, potentially leading to delayed reviews or approvals of your drug or biologic submissions.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Nonclinical Testing Terminology.

Key regulatory references include:

Course SKU
FR-26-2220-1

About Benchmarks:

Are you ready for this regulation? Use this benchmark to find out.

Each benchmark is build directly for the federal regulation.  They reflect the learning objectives of the related course.

The benchmark is not a “trivia test” – they help you evaluate your readiness to apply the new regulation.

Contact us for more information and/or personalized benchmarks for your specific organization/industry.

FDA Nonclinical Testing Terminology Rule: Key Regulatory Updates for Drug and Biologic Submissions

This course delivers a focused breakdown of the FDA’s direct final rule that replaces outdated terminology in human drug and biological product regulations. Learn exactly how to update your regulatory submissions and internal documentation by adopting ‘nonclinical’ instead of ‘animal’, ‘preclinical’, or ‘in vitro’ in all relevant contexts. Master the new definitions as they apply to IND, NDA, BLA, and postmarketing materials. Ensure your organization is prepared for the compliance deadline and avoids costly regulatory delays.

In this course you will learn the following:
* Identify the key terminology changes and their regulatory context.
* Understand the expanded definition of “nonclinical test” and “nonclinical study.”
* Apply the new terminology in regulatory submissions and communications.
* Recognize the impact of these changes on compliance and reporting.
* Understand the consequences of non-compliance with the updated regulations.

NOTE: Unless otherwise indicated, all Benchmarks are free of charge!

Why This Course is Important
Without this course, you risk non-compliance with the FDA’s updated terminology, potentially leading to delayed reviews or approvals of your drug or biologic submissions.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Nonclinical Testing Terminology.

Key regulatory references include:

Course SKU
FR-26-2220-1

Replenish your Studio Course Advisor Unit balance here . Please contact frsales@courseavenue.com if you need to purchase more. Talk to use about an Enterprise License to see if that is right for you!

FDA Nonclinical Testing Terminology Rule: Key Regulatory Updates for Drug and Biologic Submissions

$49.99

Why This Course is Important
Without this course, you risk non-compliance with the FDA’s updated terminology, potentially leading to delayed reviews or approvals of your drug or biologic submissions.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Nonclinical Testing Terminology.

Key regulatory references include:

Course SKU
FR-26-2220-1

This course delivers a focused breakdown of the FDA’s direct final rule that replaces outdated terminology in human drug and biological product regulations. Learn exactly how to update your regulatory submissions and internal documentation by adopting ‘nonclinical’ instead of ‘animal’, ‘preclinical’, or ‘in vitro’ in all relevant contexts. Master the new definitions as they apply to IND, NDA, BLA, and postmarketing materials. Ensure your organization is prepared for the compliance deadline and avoids costly regulatory delays.

In this course you will learn the following:
* Identify the key terminology changes and their regulatory context.
* Understand the expanded definition of “nonclinical test” and “nonclinical study.”
* Apply the new terminology in regulatory submissions and communications.
* Recognize the impact of these changes on compliance and reporting.
* Understand the consequences of non-compliance with the updated regulations.

Related products